Clinical Trial

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Name: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma — clinical trial record (NCT06158386)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-12-05; most recent amendment 2025-02-18.

Trial Details

NCT Number	NCT06158386
Lead Sponsor	The First Affiliated Hospital of Xiamen University Collaborators: Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Jieyang People's Hospital, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital
Conditions	Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Enrollment	33 participants
Start Date	2023-11-22
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-19